RegeneRx Biopharmaceuticals, Inc. filed its 10-K on Mar 30, 2022 for the period ending Dec 31, 2021. In this report its auditor, CohnReznick LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0014 USD | 0.00% | 0.00% | +16.67% |
1st Jan change | Capi. | |
---|---|---|
+16.67% | 2.11T | |
+0.10% | 9.14TCr | |
+3.16% | 4.11TCr | |
-11.40% | 3.43TCr | |
+53.99% | 2.53TCr | |
-9.50% | 1.28TCr | |
-12.25% | 1.16TCr | |
-44.00% | 1.14TCr | |
+5.77% | 915.59Cr | |
-6.90% | 821.79Cr |
- Stock Market
- Equities
- RGRX Stock
- News RegeneRx Biopharmaceuticals, Inc.
- RegeneRx Biopharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt